1.

Assembly of a cohort of children treated for acute myeloid leukemia at free-standing children's hospitals in the United States using an administrative database

Administrative data were used to establish a multi-center cohort of 1,686 children treated acute myeloidleukemia (AML). The cohort assembly process, which included myeloid leukemia ICD-9 discharge diagnosis codes and manual review of induction chemotherapy, was validated by chart review at a single institution. This cohort is representative for US and provides a reliable source for future comparative effectiveness and clinical epidemiology studies in pediatric AML.

F.15 Development of a new information system/databases

COBISS.SI-ID: 669356

2.

Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States

This study is the first comprehensive analyses of the US national trends in pediatric AML induction mortality and resource utilization. Using resource utilization data as a proxy for adverse events, adverse event rates reported on clinical trials substantially underestimated the clinical toxicities of all pediatric AML induction regimens.

F.22 Improvement to existing health/diagnostic methods/procedures

COBISS.SI-ID: 668844

3.

Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding Children's Hospitals across the United States

We aimed to describe the pharmacoepidemiology of rituximab use in children and to estimate the frequency of infectious events within a 1-year period after rituximab exposure. This was a retrospective cohort study of patients who received rituximab at 1 of 42 children's hospitals contributing data to the Pediatric Health Information System. A total of 2875 patients with 4639 rituximab admissions were identified. The rate of rituximab admissions increased from 3 to 185 per 100.000 admissions per year over the study interval. During the 1-year follow-up period, 463 patients (16%) died, 6.1% were diagnosed with sepsis and 2.0% with septic shock. The frequency of sepsis ranged from 2.4% in patients with autoimmune diseases to 12.2% in those with primary immunodeficiencies. Three patients were assigned an ICD-9-CM discharge diagnosis code for Pneumocystis joroveci pneumonia, 1 patient was assigned an ICD-9-CM discharge diagnosis code for hepatitis B, and 1 patient was assigned an ICD-9-CM discharge diagnosis code for progressive multifocal leukoencephalopathy. Based on ICD-9-CM code data, the rates of sepsis and other life-threatening infections after rituximab exposure vary depending on the underlying condition. Based on surveillance of infection using ICD-9-CM diagnosis codes, the rates of opportunistic infections appear to be low.

F.02 Acquisition of new scientific knowledge

COBISS.SI-ID: 669100